Skip to content
You are now leaving https://www.ionispharma.com to visit

Isis Reports Phase 2 Data on ISIS-APOCIII Rx Showing Significant Reductions in Triglycerides and APOC-III in Patients With High Triglycerides and Type 2 Diabetes